Real-World Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan: A Retrospective Health Administrative Data Analysis
Use of ARSIs for mCSPC is increasing, but ADT alone and ADT plus NSAA are still frequently used. The longer treatment duration among patients who received ARSIs indicates that treatment intensification with ARSIs is vital for mCSPC disease control.
Authors
- Fumiko Kiyonaga
- Taketo Kawai (ORCID: https://orcid.org/0000-0002-7279-2874)
- Atsushi Saito (ORCID: https://orcid.org/0000-0003-2425-3371)
- Hirotaka Shibata (ORCID: https://orcid.org/0000-0001-6506-4820)
- Yusuke Tanaka (ORCID: https://orcid.org/0000-0002-3987-1589)
Institutions
- Astellas Pharma (Japan) (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1007/s12325-025-03437-8
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52